These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 34544381

  • 21. Long-term satisfaction with curative treatment and follow-up in prostate cancer survivors.
    Monsen KV, Fosså SD, Myklebust TÅ, Smeland S, Dahl AA, Stensvold A.
    Acta Oncol; 2022 Mar; 61(3):357-362. PubMed ID: 35103559
    [Abstract] [Full Text] [Related]

  • 22. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 23. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [Abstract] [Full Text] [Related]

  • 24. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ, Zhang Z, Chan DW, Reese AC, Bivalacqua TJ, Partin AW, Walsh PC.
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [Abstract] [Full Text] [Related]

  • 25. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
    Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E.
    BMC Cancer; 2010 Apr 19; 10():152. PubMed ID: 20403178
    [Abstract] [Full Text] [Related]

  • 26. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, Karnes RJ.
    Eur Urol; 2016 Jan 19; 69(1):135-42. PubMed ID: 25865061
    [Abstract] [Full Text] [Related]

  • 27. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
    Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.
    Eur Urol; 2015 Jul 19; 68(1):123-31. PubMed ID: 25465337
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Nov 19; 78(5):661-669. PubMed ID: 32624288
    [Abstract] [Full Text] [Related]

  • 31. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
    J Urol; 2003 Nov 19; 170(5):1872-6. PubMed ID: 14532796
    [Abstract] [Full Text] [Related]

  • 32. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.
    Lancet Oncol; 2016 Jun 19; 17(6):747-756. PubMed ID: 27160475
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
    Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM.
    J Urol; 2000 Apr 19; 163(4):1155-60. PubMed ID: 10737486
    [Abstract] [Full Text] [Related]

  • 36. An Examination of the Role of Socioeconomic Status in the Relationship between Depression and Prostate Cancer Survivorship in a Population-Based Sample of Men from Atlantic Canada.
    Ilie G, Rutledge R, Sweeney E.
    Oncology; 2021 Apr 19; 99(4):260-270. PubMed ID: 33486485
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA, Katcher J, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811
    [Abstract] [Full Text] [Related]

  • 40. Self-identity after cancer: "survivor", "victim", "patient", and "person with cancer".
    Park CL, Zlateva I, Blank TO.
    J Gen Intern Med; 2009 Nov 15; 24 Suppl 2(Suppl 2):S430-5. PubMed ID: 19838845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.